Table of Contents
1: EXECUTIVE SUMMARY
INTRODUCTION
SCOPE AND METHODOLOGY
MARKET SUMMARY
Figure 1-1: Summary: Top 10 of the Top 50 Biotechnology Companies by Biologic Revenues 2017 ($ billions)
2: INTRODUCTION
BIOPHARMACEUTICALS AND BIOTHERAPEUTICS
Biopharmaceuticals
Biotechnology
Areas of Treatment for Biopharmaceuticals
REGULATIONS FOR BIOPHARMACEUTICALS
3: 50 KEY BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: PROFILES
ABBVIE
Table 3-1: AbbVie Corporate Summary
Company Overview
Table 3-2: Selected AbbVie Biopharmaceutical Products
Table 3-3: Selected Biopharmaceuticals in Development
Table 3-4: Selected Corporate Developments
Company Financials
Table 3-5: AbbVie (2015-2017) ($ millions)
AGILENT TECHNOLOGIES INC.
Table 3-6: Agilent Corporate Summary
Company Overview
Figure 3-1: Agilent Regional Breakdown by % (Americas, Europe, Asia Pacific, Rest of World)
Company Financials
Table 3-7: Agilent (2015-2017) ($ millions)
ALEXION PHARMACEUTICALS INC
Table 3-8: Alexion Corporate Summary
Company Overview
Figure 3-2: Alexion Regional Breakdown by % (US, Europe, Asia Pacific, Rest of World)
Table 3-9: Selected Alexion Biopharmaceutical Products
Table 3-10: Selected Alexion Biopharmaceuticals in Development
Company Financials
Table 3.11: Alexion (2015-2017) ($ millions)
ALLERGAN PLC
Table 3-12: Allergan Corporate Summary
Company Overview
Table 3-13: Selected Corporate Developments
Company Financials
Table 3-14: Allergan (2015-2017) ($ millions)
AMBRY GENETICS
Table 3-15: Ambry Genetics Corporate Summary
Company Overview
AMGEN, INC
Table 3-16: Amgen Corporate Summary
Company Overview
Figure 3-3: Amgen Regional Breakdown by % (US, Rest of World)
Table 3-17: Selected Biopharmaceutical Products
Table 3-18: Selected Amgen Biopharmaceuticals in Development
Table 3-19: Selected Corporate Developments
Company Financials
Table 3-20: Amgen (2015-2017) ($ millions)
ASTRAZENECA PLC
Table 3-21: AstraZeneca Corporate Summary
Company Overview
Figure 3-4: AstraZeneca Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-22: Selected Biopharmaceuticals Products
Table 3-23: Selected Biopharmaceuticals in Development
Table 3-24: Selected Corporate Developments
Company Financials
Table 3-25: AstraZeneca (2015-2017) ($ millions)
BAYER AG
Table 3-26: Bayer AG Corporate Summary
Company Overview
Figure 3-5: Bayer Regional Breakdown by % (North America, EMEA, Asia Pacific, Latin America, Rest of World)
Table 3-27: Selected Bayer AG Biopharmaceutical Products
Table 3-28: Selected Biopharmaceuticals in Development
Table 3-29: Selected Corporate Developments
Company Financials
Table 3-30: Bayer (2015-2017) ($ millions)
BERRY GENOMICS CO LTD.
Table 3-31: Berry Genomics Corporate Summary
Company Overview
BIOGEN
Table 3-32: Biogen Corporate Summary
Company Overview
Figure 3-6: Biogen Regional Breakdown by % (US, Rest of World)
Table 3-33: Selected Biopharmaceutical Products
Table 3-34: Selected Biopharmaceuticals in Development
Table 3-35: Selected Corporate Developments
Company Financials
Table 3-36: Biogen (2015-2017) ($ millions)
BIOMARIN PHARMACEUTICAL INC
Table 3-37: BioMarin Pharmaceutical Corporate Summary
Company Overview
Figure 3-7: BioMarin Regional Breakdown by % (US, Europe, Latin America, Rest of World)
Table 3-38: Selected Biopharmaceuticals Products
Table 3-39: Selected Biopharmaceuticals in Development
Company Financials
Table 3-40: BioMarin (2014-2017) ($ millions)
BRISTOL MYERS SQUIBB
Table 3-41: Bristol Myers Squibb Corporate Summary
Company Overview
Figure 3-8: BMS Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-42: Selected Biopharmaceutical Products
Table 3-43: Selected Biopharmaceuticals in Development
Table 3-44: Selected Corporate Developments
Company Financials
Table 3-45: BMS (2015-2017) ($ millions)
CELGENE
Table 3-46: Celgene Corporate Summary
Company Overview
Figure 3-9: Celgene Regional Breakdown by % (US, Europe, Rest of World)
Table 3-47: Selected Biopharmaceutical Products
Table 3-48: Selected Biopharmaceuticals in Development
Table 3-49: Selected Corporate Developments
Company Financials
Table 3-50: Celgene (2015-2017) ($ millions)
CRISPR THERAPEUTICS AG
Table 3-51: CRISPR Therapeutics Corporate Summary
Company Overview
Table 3-52: Selected Corporate Developments
Company Financials
Table 3-53: CRISPR (2015-2017) ($ thousand)
CSL BEHRING
Table 3-54: CSL Behring Corporate Summary
Company Overview
Table 3-55: Selected Biopharmaceutical Products
Table 3-56: Selected Biopharmaceuticals in Development
Company Financials
Table 3-57: CSL Behring (2015-2017) ($ millions)
- REDDY’S LABORATORIES LIMITED
Table 3-58: Dr Reddy’s Laboratories Corporate Summary
Company Overview
Company Financials
Table 3-59: Dr Reddy’s Laboratories (2015-2017) ($ millions)
ELI LILLY & CO
Table 3-60: Eli Lilly Corporate Summary
Company Overview
Figure 3-10: Eli Lilly Regional Breakdown % (US, Rest of World)
Table 3-61: Selected Biopharmaceutical Products
Table 3-62: Selected Biopharmaceuticals in Development
Table 3-63: Selected Corporate Developments
Company Financials
Table 3-64: Eli Lilly (2015-2017) ($ millions)
ENZO BIOCHEM, INC
Table 3-65: Enzo Biochem Corporate Summary
Company Overview
Company Financials
Table 3-66: Enzo Biochem (2014-2017) ($ thousands)
EVOTEC AG
Table 3-67: Evotec AG Corporate Summary
Company Overview
Figure 3-11: Evotec Regional Breakdown by % (Europe, US, Rest of World)
Table 3-68: Selected Corporate Developments
Company Financials
Table 3-69: Evotec (2015-2017) ($ Thousands)
EXELIXIS
Table 3-70: Exelixis Corporate Summary
Company Overview
Figure 3-12: Exelixis Regional Breakdown by % (US, Europe, Japan)
Table 3-71: Selected Biopharmaceutical Products
Table 3-72: Selected Biopharmaceuticals in Development
Table 3-73: Selected Corporate Developments
Company Financials
Table 3-74: Exelixis (2015-2017) ($ thousands)
GENMAB
Table 3-75: Genmab Corporate Summary
Company Overview
Table 3-76: Selected Biopharmaceutical Products
Table 3-77: Selected Biopharmaceuticals in Development
Table 3-78: Selected Corporate Developments
Company Financials
Table 3-79: Genmab (2015-2017) ($ thousands)
GILEAD SCIENCES
Table 3-80: Gilead Sciences Corporate Summary
Company Overview
Figure 3-13: Gilead Sciences Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-81: Selected Biopharmaceuticals in Development
Table 3-82: Selected Corporate Developments
Company Financials
Table 3-83: Gilead (2015-2017) ($ millions)
GLAXOSMITHKLINE
Table 3-84: GlaxoSmithKline Corporate Summary
Company Overview
Figure 3-14: GSK Regional Breakdown by % (US, Europe, Rest of World)
Table 3-85: Selected Biopharmaceutical Products
Table 3-86: Selected Biopharmaceuticals in Development
Table 3-87: Selected Corporate Developments
Company Financials
Table 3-88: GSK (2015-2017) ($ millions)
GRIFOLS INTERNATIONAL S.A.
Table 3-89: Grifols International S.A. Corporate Summary
Company Overview
Figure 3-15: Grifols Regional Breakdown by % (North America, Europe, Rest of World)
Table 3-90: Selected Biopharmaceutical Products
Table 3-91: Selected Corporate Development
Company Financials
Table 3-92: Grifols (2015-2017) ($ millions)
GUARDANT HEALTH
Table 3-93: Guardant Health Corporate Summary
Company Overview
ILLUMINA
Table 3-94: Illumina Corporate Summary
Company Overview
Company Financials
Table 3-95: Illumina (2015-2017) ($ millions)
INCYTE CORPORATION
Table 3-96: Incyte Corporate Summary
Company Overview
Table 3-97: Selected Biopharmaceutical Products
Table 3-98: Selected Biopharmaceuticals in Development
Table 3-99: Selected Corporate Development
Company Financials
Table 3-100: Incyte (2015-2017) ($ millions)
JOHNSON & JOHNSON
Table 3-101: Johnson & Johnson Corporate Summary
Company Overview
Figure 3-16: J&J Regional Breakdown by % (US, Europe, Asia Pacific/Africa, Rest of World)
Table 3-102: Selected Biopharmaceutical Products
Table 3-103: Selected Biopharmaceuticals in Development
Table 3-104: Selected Corporate Developments
Company Financials
Table 3-105: J&J (2015-2017) ($ millions)
MERCK & CO, INC.
Table 3-106: Merck Corporate Summary
Company Overview
Figure 3-17: Merck Regional Breakdown by % (US, EMEA, Japan, Asia Pacific, Latin America, Rest of World)
Table 3-107: Selected Biopharmaceutical Products
Table 3-108: Selected Biopharmaceuticals in Development
Table 3-109: Selected Corporate Developments
Company Financials
Table 3-110: Merck (2015-2017) ($ millions)
MYLAN
Table 3-111: Mylan Corporate Summary
Company Overview
Figure 3-18: Mylan Regional Breakdown by % (North America, Europe, Rest of World)
Company Financials
Table 3-112: Mylan (2015-2017) ($ millions)
MYRIAD GENETICS
Table 3-113: Myriad Genetics Corporate Summary
Company Overview
Table 3-114: Selected Corporate Developments
Company Financials
Table 3-115: Myriad (2015-2017) ($ millions)
NOVARTIS INTERNATIONAL AG
Table 3-116: Novartis Corporate Summary
Company Overview
Figure 3-19: Novartis Regional Breakdown by % (US, Europe, Asia Pacific, Rest of World)
Table 3-117: Selected Biopharmaceutical Products
Table 3-118: Selected Biopharmaceuticals in Development
Table 3-119: Selected Corporate Developments
Company Financials
Table 3-120: Novartis (2015-2017) ($ millions)
NOVO NORDISK A/S
Table 3-121: Novo Nordisk Corporate Summary
Company Overview
Figure 3-20: Novo Nordisk Regional Breakdown by % (North America, Europe, Japan, South Korea, China, Rest of World)
Table 3-122: Selected Biopharmaceutical Products
Table 3-123: Selected Biopharmaceuticals in Development
Company Financials
Table 3-124: Novo Nordisk (2015-2017) ($ millions)
ORGANOGENESIS
Table 3-125: Organogenesis Corporate Summary
Company Overview
OXFORD NANOPORE TECHNOLOGIES
Table 3-126: Oxford Nanopore Technologies Corporate Summary
Company Overview
PERKIN ELMER, INC
Table 3-127: Perkin Elmer Corporate Summary
Company Overview
Table 3-128: Selected Corporate Developments
Company Financials
Table 3-129: PerkinElmer (2015-2017) ($ millions)
PFIZER
Table 3-130: Pfizer Corporate Summary
Company Overview
Figure 3-21: Pfizer Regional Breakdown by % (US, Japan, Rest of World)
Table 3-131: Selected Biopharmaceutical Products
Table 3-132: Selected Biopharmaceuticals in Development
Table 3-133: Selected Corporate Developments
Company Financials
Table 3-134: Pfizer (2015-2017) ($ millions)
PRECISION BIOSCIENCES INC
Table 3-135: Precision BioSciences Corporate Summary
Company Overview
QIAGEN N.V.
Table 3-136: QIAGEN Corporate Summary
Company Overview
Figure 3-22: QIAGEN Regional Breakdown by % (Americas, EMEA, Asia Pacific & Rest of World)
Table 3-137: Selected Corporate Developments
Company Financials
Table 3-138: QIAGEN (2015-2017) ($ millions)
REGENERON PHARMACEUTICALS
Table 3-139: Regeneron Corporate Summary
Company Overview
Table 3-140: Selected Biopharmaceutical Products
Table 3-141: Selected Biopharmaceuticals in Development
Table 3-142: Selected Corporate Developments
Company Financials
Table 3-143: Regeneron (2015-2017) ($ millions)
ROCHE LTD.
Table 3-144: Roche Corporate Summary
Company Overview
Figure 3-23: Roche Regional Breakdown by % (North America, Europe, Japan, Asia Pacific, Rest of World)
Table 3-145: Selected Biopharmaceutical Products
Table 3-146: Selected Biopharmaceuticals in Development
Company Financials
Table 3-147: Roche (2015-2017) ($ millions)
SANOFI
Table 3-148: Sanofi Corporate Summary
Company Overview
Figure 3-24: Sanofi Regional Breakdown by % (US, Europe, Rest of World)
Table 3-149: Selected Biopharmaceutical Products
Table 3-150: Selected Biopharmaceuticals in Development
Table 3-151: Selected Corporate Developments
Company Financials
Table 3-152: Sanofi (2015-2017) ($ millions)
SEATTLE GENETICS, INC
Table 3-153: Seattle Genetics Corporate Summary
Company Overview
Table 3-154: Selected Biopharmaceuticals in Development
Table 3-155: Selected Corporate Developments
Company Financials
Table 3-156: Seattle Genetics (2015-2017) ($ millions)
SHIRE
Table 3-157: Shire Corporate Summary
Company Overview
Table 3-158: Selected Biopharmaceutical Products
Table 3-159: Selected Biopharmaceuticals in Development
Table 3-160: Selected Corporate Development
Company Financials
Table 3-161: Shire (2015-2017) ($ millions)
TAKEDA
Table 3-162: Takeda Corporate Summary
Company Overview
Figure 3-25: Takeda Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-163: Selected Biopharmaceutical Products
Table 3-164: Selected Biopharmaceuticals in Development
Table 3-165: Selected Corporate Developments
Company Financials
Table 3-166: Takeda (2015-2017) ($ millions)
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Table 3-167: Teva Corporate Summary
Company Overview
Figure 3-26: Teva Regional Breakdown by % (US, Europe, Rest of World)
Table 3-168: Selected Biopharmaceutical Products
Table 3-169: Selected Biopharmaceuticals in Development
Table 3-170: Selected Corporate Developments
Company Financials
Table 3-171: Teva (2015-2017) ($ millions)
THERMO FISHER SCIENTIFIC, INC
Table 3-172: Thermo Fisher Scientific Corporate Summary
Company Overview
Table 3-173: Selected Corporate Developments
Company Financials
Table 3-174: Thermo Fisher Scientific (2015-2017) ($ millions)
UCB S.A.
Table 3-175: UCB Corporate Summary
Company Overview
Table 3-176: Selected Biopharmaceuticals in Development
Table 3-177: Selected Corporate Developments
Company Financials
Table 3-178: UCB (2015-2017) ($ millions)
UNITED THERAPEUTICS CORPORATION
Table 3-179: United Therapeutics Corporate Summary
Company Overview
Table 3-180: Selected Biopharmaceuticals in Development
Company Financials
Table 3-181: United Therapeutics (2015-2017) ($ millions)
WATERS CORPORATION
Table 3-182: Waters Corporate Summary
Company Overview
Figure 3-27: Waters Regional Breakdown by % (US, Europe, Asia, Rest of World)
Company Financials
Table 3-183: Waters (2015-2017) ($ millions)
